RecruitingNot applicableNCT06850766

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ottawa Hospital Research Institute
Principal Investigator
Terry Ng, MD
The Ottawa Hospital Cancer Centre
Intervention
Morning administration of TMZ(other)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
2025 – 2031

Study locations (2)

Collaborators

The Ottawa Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06850766 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials